secwatch.observer — SEC 8-K summary
======================================

Issuer:     BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
CIK:        0001137883
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001104659-24-119041
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BrainStorm Q3 net loss widens to $2.7M, cash at $0.35M; advancing NurOwn Phase 3b trial
--------------------------------------------------------------------------------

- Cash, equivalents, restricted cash only $0.35M as of Sept 30, 2024; net loss $2.7M ($0.51/shr) vs $1.2M ($0.45) YoY.
- R&D expenses fell to $1M from $3.3M; G&A to $2M from $2.7M.
- Signed MOU with Pluri Inc. to manufacture NurOwn for planned Phase 3b ALS trial enrolling ~200 participants.
- Phase 3b: 24-week placebo-controlled part (Part A) then 24-week open-label (Part B); primary endpoint: ALSFRS-R change at week 24.
- Expanded Access data showed median survival 46.6 vs 41.1 months (p=0.0379) and consistent reductions in neurofilament light.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924119041/0001104659-24-119041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1137883/000110465924119041/tm2428354d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-119041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer